Ardelyx Valuation Multiples

Ardelyx Overview

About Ardelyx

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Founded

2007

HQ

Employees

489

Website

ardelyx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $438M

EBITDA: ($22M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Ardelyx Financials

Ardelyx reported last 12-month revenue of $438M and negative EBITDA of ($22M).

In the same LTM period, Ardelyx generated $400M in gross profit, ($22M) in EBITDA losses, and had net loss of ($48M).

Ardelyx P&L

In the most recent fiscal year, Ardelyx reported revenue of $407M and EBITDA of ($29M).

Ardelyx expects next 12-month revenue of XXX and NTM EBITDA of XXX

Ardelyx Stock Performance

Ardelyx has current market cap of $2B, and enterprise value of $2B.

Ardelyx's stock price is $6.46.

Ardelyx Valuation Multiples

Ardelyx trades at 3.5x EV/Revenue multiple, and (69.3x) EV/EBITDA.

Ardelyx Financial Valuation Multiples

As of March 21, 2026, Ardelyx has market cap of $2B and EV of $2B.

Equity research analysts estimate Ardelyx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ardelyx has a P/E ratio of (32.9x).

Ardelyx Margins & Growth Rates

Ardelyx's revenue in the last 12 month grew by 35%.

Ardelyx's revenue per employee in the last FY averaged $0.9M.

Ardelyx's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ardelyx's rule of X is 82% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Ardelyx Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Ardelyx M&A Activity

Ardelyx acquired XXX companies to date.

Last acquisition by Ardelyx was on XXXXXXXX, XXXXX. Ardelyx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Ardelyx Investment Activity

Ardelyx invested in XXX companies to date.

Ardelyx made its latest investment on XXXXXXXX, XXXXX. Ardelyx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).